FAIRFIELD, Conn.--(BUSINESS WIRE)--Aug. 24, 2004--GE today announces the appointment of five new company officers.
Peter Ehrenheim, 49, is President, Protein Separations, GE Healthcare Bio-Sciences, a role he initially assumed for Amersham in 1999. Peter is based in Uppsala, Sweden. In 1998, he was named Vice President, North American Manufacturing, Amersham Pharmacia Biotech. Prior to that, Peter had a succession of roles within Pharmacia Biotech starting in 1983, until it the company was acquired by Amersham in 1997. Peter received his MSc in Mechanical Engineering from the Royal Institute of Technology in Stockholm, Sweden in 1980.
William R. (Bill) Clarke, 52, is Vice President, Chief Technology & Medical Officer, GE Healthcare. Prior to that Bill was Executive Vice President, Research & Development, Amersham Health, a role he served in from 2000 to 2004. Bill was Director, Disease Science Research for Glaxo Welcome from 1997-2000. Bill received his M.D. and M.S. in Physiology and Pharmacology from Duke University in 1979 and his B.A. in Chemistry from Duke in 1974. He was a practicing academic physician for 15 years with a specialty in pediatric critical care and pediatric anesthesiology and a research interest in pulmonary pharmacology and genetics. Bill is Board Certified in Pediatrics. Anesthesiology, Pediatric Critical Care and Adult Critical Care.
Elizabeth Lee, 43, is Vice President, General Counsel, GE Consumer Finance. She was previously General Counsel, GE Global Consumer Finance and joined GE in 1995 as Legal Director for GE Consumer Finance's United Kingdom business. Elizabeth graduated from the College of Law in London in 1984 and received a BA in Jurisprudence from Oxford University in 1983.
Christopher Perretta, 46, is Vice President, Chief Information Officer, GE Commercial Finance. He was previously Chief Information Officer for GE Consumer Finance North America, and Chief Technology Officer for GE Capital. Christopher began his GE career in December, 1996, as Director, Information Technology, GE Capital Corporate. Christopher received his M.S. in Electrical Engineering from Syracuse University in 1980 and his B.S. in Electrical Engineering from Johns Hopkins University in 1979.
Daniel L. Peters, 52, is President, Medical Diagnostics, GE Healthcare Bio-Sciences, a role he assumed in April 2004, upon the acquisition of Amersham plc by GE Healthcare. Prior to that, he was Chief Operating Officer, Amersham Health and President, Medical Diagnostics, Amersham Health. Previously, Dan held roles of increasing responsibility within the U.S. pharmaceuticals business of Sterling Winthrop over a 17-year tenure, becoming President of the U.S. Pharmaceutical business in 1993. Dan received his B.S. in Education from Western Illinois University in 1975.
GE (NYSE: GE) is a diversified technology, media and financial services company dedicated to creating products that make life better. From aircraft engines and power generation to financial services, medical imaging, television programming, and plastics, GE operates in more than 100 countries and employs more than 300,000 people worldwide. For more information, visit the company's Web site at http://www.ge.com.
Caution Concerning Forward-Looking Statements
This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of GE. Forward-looking statements are based on management's current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from these expectations and assumptions due to changes in global political, economic, business, competitive, market, regulatory and other factors. We undertake no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise. This presentation includes certain non-GAAP financial measures as defined under SEC rules. As required by SEC rules, we have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in this press release.
--30--AC/ny*
CONTACT:
General Electric, Fairfield
Linda Boff, 203-373-2989